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In March 2005, a group of experts from the European Society of Human Genetics and European Society of Human
Reproduction and Embryology met to discuss the interface between genetics and assisted reproductive technology (ART),
and published an extended background paper, recommendations and two Editorials. Seven years later, in March 2012,
a follow-up interdisciplinary workshop was held, involving representatives of both professional societies, including experts from
the European Union Eurogentest2 Coordination Action Project. The main goal of this meeting was to discuss developments at
the interface between clinical genetics and ARTs. As more genetic causes of reproductive failure are now recognised and an
increasing number of patients undergo testing of their genome before conception, either in regular health care or in the context
of direct-to-consumer testing, the need for genetic counselling and preimplantation genetic diagnosis (PGD) may increase.
Preimplantation genetic screening (PGS) thus far does not have evidence from randomised clinical trials to substantiate that
the technique is both effective and efficient. Whole-genome sequencing may create greater challenges both in the technological
and interpretational domains, and requires further reflection about the ethics of genetic testing in ART and PGD/PGS.
Diagnostic laboratories should be reporting their results according to internationally accepted accreditation standards
(International Standards Organisation – ISO 15189). Further studies are needed in order to address issues related to the
impact of ART on epigenetic reprogramming of the early embryo. The legal landscape regarding assisted reproduction is
evolving but still remains very heterogeneous and often contradictory. The lack of legal harmonisation and uneven access to
infertility treatment and PGD/PGS fosters considerable cross-border reproductive care in Europe and beyond. The aim of this
paper is to complement previous publications and provide an update of selected topics that have evolved since 2005.
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In 2004, the Public and Professional Policy Committee1–4 of the
European Society of Human Genetics (ESHG)5 felt the need for
professional recommendations on how to use assisted reproductive
technologies (ARTs) safely and reliably from the genetic point of view,
as well as issuing guidelines on acceptable goals of ART-based
treatment and its prioritisation in European healthcare systems.
It was thus decided to approach the European Society of Human
Reproduction and Embryology (ESHRE)6 to undertake such work
together. After several preparatory meetings of a working group,
a joint ESHG/ESHRE meeting was held in Seville, 31 March to 1 April
2005 and a paper summarising the meeting was published,1 together
with joint recommendations endorsed by the ESHG and ESHRE in
both society journals3,7 and an Editorial.2
Seven years later, on 5–6 March 2012, an expert group of the
ESHG, ESHRE and EuroGentest2 representatives met again in
Brussels to assess the changes that had occurred in the field and to
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update the common background document, wherever needed, with
selected issues. The result of these deliberations and review of the
literature until May 2013 are presented in this paper.
METHODS
Selected topics relating to current issues in ARTs and reproductive genetics
were discussed by an expert panel, in order to reflect developments in the field,
both from research and clinical perspectives.
RESULTS
Substantial advances have occurred in the field of ART, including
greatly expanded knowledge of the genetic causes of male and female
reproductive failure. The relationship between the epigenome and
infertility is still under investigation. Currently, the analysis of
potential epigenetic and transgenerational effects of ART is still
impossible in the absence of sizeable second- and third-generation
study cohorts. In preimplantation genetic diagnosis (PGD), there has
been an increased move to blastocyst biopsy and the use of new
technologies for diagnosis, such as array comparative genomic
hybridisation (aCGH).
A recent meta-analysis of preimplantation genetic screening
(PGS) has shown that using fluorescent in situ hybridisation
(FISH), PGS results in a significantly lower live-birth rate.8
A recently published pilot randomised clinical trial (RCT) using
aCGH showed an increase in implantation and ongoing pregnancy
rates following chromosome screening on day 5, but reported a low
pregnancy rate in the control group.9 More RCTs using newer
technologies (aCGH, single-nucleotide polymorphism (SNP)
arrays and sequencing) are necessary to make a decision on the
utility of such approaches.
According to the Organisation for Economic Cooperation and
Development (OECD) Guidelines for Quality Assurance in Molecular
Genetic Testing,10 both PGD and PGS should be reported by
accredited laboratories (International Standards Organisation – ISO
15189)11 or equivalent accreditation schemes.12
An increasing spectrum of genetic tests are being offered directly to
the consumer (DTC)13 or directly through a physician without proper
medical advice and/or appropriate genetic counselling.14 High-
throughput genomic technologies currently comprising whole-
exome sequencing (WES)/whole-genome sequencing (WGS) not
only offer great potential in reproductive genetics15 but also pose
substantial challenges regarding their clinical utility, interpretation of
results, detection of variants of unknown clinical significance and
incidental (or unsought for) findings, including a variety of ethical
issues for the index case and their relatives.16,17 Many of the advances
in the field are primarily driven by rapidly developing technologies,
with the healthcare services being unable to adequately cope
with testing outcomes in terms of counselling and proper medical
follow-up.
There have been several studies examining the genetic effects of
assisted reproduction, from population genetics and the birth
defects-related perspectives.18–21 Further studies and/or meta-
analyses of studies utilising different methodologies, and eventually
transgenerational follow-up, need to be performed in order to address
some initial concerns in larger representative cohorts. In this regard,
regular updates from the ESHRE PGD Consortium will be of vital
importance.22
Although legal aspects related to medically assisted reproduction
are continually being revised in Europe, substantial heterogeneity
remains and fosters cross-border reproductive care (CBRC).23 There
are anecdotal reports that the current difficult economic situation in
Europe, and beyond, is negatively influencing reimbursement
of ART,24 including deterioration of equal access to fertility
treatment,25 as well as to genetic testing, in general, and to PGD.
The use of stem cells is increasing our knowledge of early human
development and opens new therapeutic avenues in the area of
fertility preservation.26
The panel noted that ARTs and reproductive genetics are fast-
moving fields, with many new techniques rapidly being brought into
the clinic. However, in many instances, clinical utility, safety, efficacy,
counselling and ethical/legal aspects of these developments need to be
further analysed. Basic research needs to be undertaken, followed by
clinical trials, efficacy and safety studies, before new clinical practices
are brought into routine treatment.27,28 Follow-up of children born by
new procedures should be mandatory.
DISCUSSION OF SELECTED ISSUES
European directives
Recent European Union (EU) directives have had a significant impact
on ART. In particular, the EU Tissue and Cells Directive (EUTCD;
currently under revision)29 and the supplementing technical directives
2006/17/EC30 and 2006/86/EC31,32 have led to new safety and quality
standards for clinical and laboratory procedures performed within
in vitro fertilisation (IVF). Most European countries already
transposed them into their respective national legislations, thus
regulating procurement, testing, processing, storage, distribution
and import/export of reproductive cells and tissues. Moreover, the
EU Directive 98/79/EC33 on in vitro diagnostic medical devices,
known as the ‘IVD Directive’ is also currently under revision and may
have a significant effect on the field of genetic testing and its interface
with ART.
Cross-border reproductive care
CBRC refers to the care of patients who cross borders in search
for reproductive treatment in another country, mostly because of
local constraints. It needs to be stressed that the derogatory
colloquial term of ‘reproductive’ tourism is felt to be inappropriate.
Indeed, few people elect a priori to seek treatment away from their
support system, whether familial or through state funding, if
available, as, in general, they may feel vulnerable, isolated, not be
fluent in the local language or fear of stigmatisation on their return
home.34
The reasons for CBRC vary but are more commonly because of
legal constraints, where at least some techniques are forbidden to
all or particular population groups, such as single women or
same-sex couples. Other reasons include access limitations at
home, including availability of a given technique, long waiting
lists or age limits (eg, no national health treatment is generally
available in the United Kingdom for women over 40 years,
whereas in France state refunds are available until the age of
43 years), seeking better quality or cheaper treatment abroad, as
well as previous failure at home. There is no ethical objection
per se to CBRC, as it enhances the patient’s autonomy and it also
fits the principle of free movement of patients and expertise
within the EU.35 Other ethical issues pertain mostly to the
possibility of coercion and abuse of gamete (especially oocyte)
donors, even though in Europe the compensation for donation
must not be disproportionate to the extent that it becomes
payment, according to the EUTCD (see the section ‘European
directives’).
In spite of high media exposure, there was little data concerning
CBRC until the first international European study was published,23
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analysing the demographics, motivations and reasons for crossing
borders of patients travelling to six European countries. This study
was based on 1230 CBRC cycles recorded in 1 month, leading to a
yearly estimation of a minimum of 25 000 cycles. It confirmed that
one of the main reasons for CBRC were legal restrictions, based on
prohibition of the technique per se, or its inaccessibility related to
some patients’ characteristics (such as age, sexual orientation or civil
status). It also highlighted that people tend to travel to the nearest
country where the required technique is available. Examples include
Germans seeking oocyte donation in the Czech Republic or French
lesbian couples requesting donor insemination in Belgium. Some
aspects are more problematic than others, not least concerning
national law evasion, although ‘there may be good reasons for
people to bypass the law by travelling abroad’.35 A major ethical
principle and political issue is fair access,25 which should ideally be
realised in the home country.
Concerned about the joint professional responsibility of all
stakeholders involved in ART, the CBRC ESHRE Task Force also
published a Good Practice Guide (GPG) for CBRC, for the informa-
tion of patients, and all collaborators involved, including gamete
donors and surrogates.36 This guide is articulated around the
following core principles: equity, quality and safety (the last two
often conflated in the outcome of a singleton healthy birth), evidence-
based care, patient involvement, redress counselling and psychological
support, which should preferably be provided in a language in which
the recipient is fluent. The safety question is essential to care and is
covered at least practically in the EU by some specific aspects of the
EUTCD, such as laboratory conditions, and gametes donor screening
for viral illnesses as well as their ‘compensation’, where the term ‘non-
commercialisation’ is mentioned as a ‘protective’ feature against
exploitation. Indeed, the notion of compensation is at the ethical
core of donation. If compensation becomes payment, appropriate
consent may be undermined by enticement. Moreover, there may be
pressure on vulnerable, low-income women, turning them into gamete
vendors rather than donors.37 The avoidance of intermediate agencies
(‘brokerage’), which may lead to violations of GPG and, in the worst
case, to abuse of women in low-resource countries is advisable.37 Last
but not least, the welfare of the future child should be at the centre of
safety and ethical concerns, taking care of promoting the ‘decline in
the number of multiple births’, which ‘can be regulated only with a
reduction of the total number of embryos transferred’.38
Joint responsibility is of course a complex moral and legal problem,
especially when taking into account varied European legal frames.39
Information sharing across borders is essential, but increasing safety
and good practice for all concerned in CBRC is currently mostly
work in progress. For instance, the ESHRE GPG is now posted
on the websites of many national societies and regulatory bodies
within Europe,40 as well as the patients’ organisation ‘Fertility
Europe’.41
Finally, other challenges are also looming, as oocyte banking is
becoming much more efficient owing to vitrification.42 This means
that eggs have started crossing borders as well, perhaps enabling some
patients to stay at home in their preferred environment, but making it
more difficult to check the conditions of gamete donation for all
concerned.43
Genetic aspects of female infertility
Besides taking a personal and familial history, a medical examination
and the basic tests, such as hormone profiles, and medical examina-
tion of the female reproductive system, an increasing amount of
genetic tests are being offered to females suffering from infertility.
Genetic testing of females with ovarian insufficiency and amenorrhea
should consist of a chromosomal analysis and fragile X-mental
retardation-1 gene (FMR1) ‘expansion’ CGG(n) testing.44 Other
more specific tests looking for the blepharophimosis–ptosis–
epicanthus inversus syndrome caused by FOXL2 mutations,45
galactosemia (GLAT mutations),46 or less commonly POLG
mutations47 associated with a mitochondrial disease should be
performed if clinically indicated. Rarer causes of female infertility,
such as those due to mutations in the follicle-stimulating hormone
receptor or the luteinising hormone/choriongonadotropin receptor,
should also be kept in mind and investigated whenever necessary.48,49
Other rare hereditary conditions, such as Kallmann syndrome (KS),50
androgen insensitivity51 and adrenal hyperplasia may be diagnosed as
causes of female infertility.52 In cases of recurrent miscarriages
(at least three times),53 and for examining balanced translocations
and/or other structural anomalies, chromosome analysis should be
performed.52 Inherited thrombophilia testing requires standardisation
and further meta-analyses in order to substantiate its clinical utility.54
If a genetic cause of infertility is established, genetic counselling
should be provided (see the section ‘Counselling within the repro-
ductive medicine and genetic contexts’). Depending on the type of
genetic anomaly, various treatments may be offered, such as IVF, with
or without PGD, gamete or embryo donation. Further family testing
(‘cascade screening’) should be discussed. If an FMR1 (GGC)n
expansion is diagnosed in premature ovarian insufficiency,55 IVF
with PGD may help the couple to conceive a child unaffected by the
Fragile X syndrome (FXS) and further testing of family members of
the female partner has to be used. For each genetic condition
diagnosed, the appropriate therapeutics and counselling approach
should be discussed. It is important to remember that PGD may be
indicated whenever facing a genetic condition and infertility, and
should be discussed in counselling, together with all other possible
reproductive options.56,57
For the more common conditions observed in the infertile female,
such as polycystic ovary syndrome,58 endometriosis59 and certain
anomalies of the female reproductive system, no diagnostic genetic
test is available, as these conditions are multifactorial.
In conclusion, a ‘cascade’ diagnostic evaluation of an infertile
couple may allow a genetic diagnosis based on chromosomal
abnormalities or an FMR1 expansion. Further evaluations may reveal
other markedly rarer conditions. A multidisciplinary approach,
including genetic counselling, is mandatory. New technologies, such
as aCGH, WES or WGS, will probably enable identification of
additional genes that have an important role in female reproductive
failure.60
Genetic aspects of male infertility
Sperm counts (World Health Organisation criteria)61 are used for the
assessment of male fertility.62 A sperm concentration of o10 106
per ml or total sperm counts of o10–15 106 is an ‘indication
threshold’ for genetic testing. Currently, genetic testing is indicated
primarily for the elucidation/confirmation of the underlying diagnosis
and to assess the risk of infertility to the offspring (eg, when the index
case is bearing a Y chromosome microdeletion following successful
treatment by various forms of testicular sperm extraction,63 followed
by intracytoplasmatic sperm injection (ICSI).
Recently, it has been estimated that roughly one quarter of patients
with azoospermia (AZ) and severe oligozoospermia undergo genetic
testing.64 The first examination of choice is karyotyping for common
chromosomal aberrations, possibly followed by specific molecular
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tests. Interestingly, the lower the sperm count, the more chromosomal
aberrations are found.65
Gonosomal aberrations are mainly represented by the Klinefelter
syndrome66 (KFS: 47, XXY, including its various mosaic formulae)
with a rather heterogeneous clinical presentation. This is one of the
most common human chromosomal aneuploidies, with a prevalence
of B1/650 males. The majority of KFS cases are primarily diagnosed
due to infertility; about 3% of infertile and 16% of azoospermic males
have KFS.67 Currently, there is growing evidence that sperm
extraction (see above) combined with ICSI can successfully treat
some instances of KFS-related infertility68 and spermatogonial
preservation is also being developed.69 Nonetheless, long-term
studies are needed to evaluate the likelihood of a higher prevalence
of chromosomal aberrations in their offspring.
In this context, it needs to be noted that the majority of men with
chromosomal aberrations associated with infertility are apparently
healthy, and do not have dysmorphic features or intellectual disability.
Males with various forms of chromosomal translocations have a
higher risk of repeated miscarriages or stillbirth in their offspring, as
their balanced translocations may become unbalanced in their
offspring.70
Pathogenic mutations or variants in the cystic fibrosis (CF)
transmembrane receptor gene (CFTR) have been implicated in male
infertility71 and are associated with obstructive AZ due to congenital
bilateral absence of the vas deferens (CBAVD).72 This association
highlights the fact that patients with obstructive AZ are candidates for
CFTR genetic testing.73 Testing distinguishes obstructive AZ from AZ
due to Y-chromosomal microdeletions. It is important to note that
spermatogenesis in CBAVD is normal; thus, patients with CFTR-
related obstructive AZ can be treated by sperm extraction followed by
ICSI,74 with their offspring having an increased risk of CF itself.
Finally, association of congenital unilateral absence of vas deferens
(usually linked to equilateral renal and urethral developmental
anomalies) is not consistently associated with CFTR mutations.75
Various Y chromosome microdeletions are predominantly found in
non-obstructive AZ or severe oligospermia.76 Molecular genetics
diagnosis of such microdeletions is useful and feasible with a simple
and robust test.77 Association of AZ factor (AZF) – AZF1a, AZF1b,
AZF1bc and AZF1c – microdeletions with infertility is unambigu-
ous.78 Although there are marked differences in the prevalence of
these deletions between various studies (mainly due to variable
inclusion/exclusion criteria in analysed cohorts), most (ie, 475%)
of these deletions comprise the AZF1c region.79 The association to
sperm counts is proportional, in that AZ men have a higher
prevalence of microdeletions than oligospermic patients. Testing of
AZF1 microdeletions has a prognostic impact for sperm extraction,
as no sperm can be retrieved in AZF1a and AZF1b, whereas there is a
fair chance that viable sperm could be retrieved in AZF1c.80–82
In the latter instance, sperm can be found in the ejaculate,
which is a preferable source for IVF/ICSI compared with various
forms of surgical sperm extraction. Genetic counselling should
be offered to the family following fertility treatment, as the
underlying cause of male infertility will be transferred to
successive generations. The Y chromosome gr/gr deletions (NR3C1)
are more likely to occur among infertile men with quantitative
decrease of their sperm counts83 but their use in diagnostics is limited
due to their low penetrance.
Alterations in the gonadotropin-releasing hormone (GnRH) gene
(GNRH1), implicated in disturbed neuronal migration,84 were found
in congenital hypogonadotrophic hypogonadism (HH),85 which
presents as a variable syndrome characterised by low sex steroid
and gonadotropin levels, due to impaired GnRH upstream
stimulation, originating in the hypothalamus. The fully expressed
syndrome with hyposmia/anosmia is described as KS (see the section
‘Genetic aspects of female infertility’), with bulbus olfactorius agenesis
as its main feature. However, the marked underlying genetic
heterogeneity86 and variable expressivity and penetrance of such
genetic factors are confounding factors for genetic diagnosis. Various
mutations in the respective genes are found in half of the familial
cases of HH, but only exceptionally in sporadic forms. Moreover,
substantial clinical heterogeneity of HH makes genotype–phenotype
correlations difficult. Thus far, diagnostic utilisation of specific HH-
related gene mutation panels is limited and more research is needed.87
Similar conclusions are applicable to the diagnostic testing of the
androgen receptor (AR) gene.88 Mutations in this gene are found in
B1% of patients with AZ or severe oligozoospermia. It should be
noted that examination of the entire AR gene is needed. However,
detection of variants of unclear clinical significance limits the
diagnostic utility of sequencing.
Recently, reviews of SNP variants89 and genome-wide association
studies90 have provided evidence that there are multiple SNPs
significantly associated with decreased sperm counts,91 but their
functional consequence still needs to be clarified. In rare cases of
male infertility (o0.1% of all instances), molecular alterations in
SPATA16, PICK1 and DPY19L2 have been associated with
globozoospermia,92 as well as in AURKC in the sperm
macrocephaly syndrome.93 The role of alterations of the
mitochondrial DNA94 in male infertility and in association with
ICSI treatment requires further research.
Because of the advances in the use of aCGH, copy number variants
(CNVs)95 have been studied at the level of the entire genome or just
of the Y chromosome. However, in the absence of known biological
functions of affected genes, it is difficult to assess their clinical
significance and more studies are required. Additional lines of
research are necessary in order to assess the role of obesity,96 environ-
mental pollution with endocrine disruptors97 and controversial
impact of cell phone radiation98 on male fertility, to name just a
few prominent examples recently discussed in the medical literature.
It is possible that the majority of idiopathic male and female
infertility could be elucidated by WES/WGS analyses,99 but clinical
interpretation of obtained genomic data remains challenging.100 This
problem is not only due to the detection of variants of unknown
clinical significance, but is also related to the ‘clinical continuum’ with
which such variants ought to be associated with.
Finally, genomic complexity together with proteome analysis adds a
further, unexplored, level of complexity.101 Therefore, utilisation and
combination of the various ‘omics’ technologies within the systems
biology framework, together with robust bioinformatics, may bring
the necessary breakthroughs in the study of genetic causes of human
infertility. Thus, at the moment there is no routine ‘diagnostic’
indication for WES-/WGS-based approaches in male or female
infertility, that is, beyond the research setting.102
Counselling within the reproductive medicine and genetics
contexts
Genetic causes of reproductive failure are now better understood and
more thoroughly investigated, whereas counselling of infertile
couples (both reproductive and genetic) has markedly improved.2
Appropriate counselling based on the medical, family and
reproductive history should be offered and genetic testing should be
implemented when indicated. If a genetic cause is suspected, the
couple should be referred to a medical/clinical geneticist, according to
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provision in various countries.1 There is still, however, the need
to define clearly how far to investigate the causes of infertility and to
harmonise the criteria for involving specific professionals, from
reproductive counselling (by obstetricians, gynaecologists and ART
specialists) to genetic counselling performed by clinical geneticists and
genetic counsellors/nurses.
The extent of information provided in counselling should be
adapted to the particular reason for ART and PGD, as well as to
the needs of each couple. The content should include risks for
the couple (eg, ovarian hyperstimulation syndrome, waiting time,
psychosocial stress and limited pregnancy success rate), as well as to
the embryo, fetus and child to be born. This includes the low risk for
congenital malformations or genetic disease, decreased birth weight
and survival, multiple pregnancy and associated problems, and later-
life disorders, as well as the current scientific limitations and
uncertainties that still surround these techniques, and the immediate,
medium and long-term outcomes.103,104
Couples should be provided with evidence-based information on
the techniques and their implications, as well as on the performance
of an infertility clinic. Standardised information should be presented,
including clinic success rate per oocyte retrieval, delivery rate per
oocyte retrieval and the percentage of singletons born. Such bench-
marking practice may have improved but is still not applied in many
centres and countries. Local professional guidelines or other forms of
regulation (eg, statutory) are needed. Autonomy of couples has to be
respected, although professionals have a duty to convey the wider
perspective, primarily considering the future child’s interest.1,105
The possible use of genetic techniques in ART treatment is
discussed with the patients in the course of reproductive counsel-
ling56,57 as performed by the professionals working in ART settings.
Some may wish to understand these issues more thoroughly and, for
instance, ask about possible consequences related to the risk of
imprinting of genes predisposing to the common diseases of adult
age. As the oldest ‘IVF children’ are at present only about 35 years of
age, whereas the oldest ICSI child is 20 years old,106 this question
cannot be answered. Such questions may sometimes require a
discussion with a specialised professional, that is, clinical geneticist.
Genetic counselling is a communication process that involves
discussing the problems associated with a genetic condition.107,108
A typical genetic counselling consultation encompasses the familial,
scientific, psychological and social aspects of being at risk or being
affected. Key concepts in genetic counselling practice are relevant
information exchange, the presentation of choices relevant to the
patient and exploration of patient values and beliefs. In traditional
genetic counselling (of fertile prospective parents), a non-directive
approach is considered to be of paramount importance. In view of the
responsibility of the professional involved in medically assisted
reproduction to take account of the welfare of the child, however, a
more directive approach may occasionally be justified in this
particular context (see the section ‘Ethical issues related to assisted
reproduction and reproductive genetics’). Although genetic
counselling may be provided by any appropriately trained and
skilled health practitioner who has achieved the relevant core
competences,109 the term ‘genetic counsellor’ should apply only to
those who are specifically educated for this role.110
In spite of the fact that ART treatment is almost always associated
with issues requiring genetic screening/testing, genetic counselling
may not always be needed. The treatment itself may involve the use of
genetic screening methods, such as aneuploidy screening, as a part of
PGS. Furthermore, according to present knowledge, ART appears to
be associated with a small, but not negligible, risk for genetic
consequences in the form of epigenetic changes leading to congenital
disorders.111 The cause of infertility may be genetic, which may have
further implications related to the health of the offspring if the
infertile parent’s own germ cells are used. Finally, the very reason for
ART treatment may be the risk of a genetic condition in the family
and the desire for PGD. In these cases, the need for genetic
counselling is explained below and some examples are given.
Where genetic risks are related to the cause of infertility, genetic
counselling is always required. Usually, the aetiology of the infertility
is diagnosed in the infertility clinic. If the cause is genetic and there
are possible consequences for the offspring, the couple should be
referred for genetic counselling. The cause itself is explained and the
implications for the person’s close relatives (eg, siblings) are discussed
as well. The couple may feel that they need support in informing the
relatives, if needed: this can usually be provided by genetics health
professionals. The couple may be reluctant to discuss these issues
during current treatment, in which case the discussion can be planned
for later. Situations where genetic counselling should always be
extended to the family, at least to the siblings of the index case,
include chromosomal translocations and some conditions leading to
female infertility (eg, ovarian dysfunction in FMR1 premutation
carriers) or male infertility (especially in mutations/variants of CFTR
leading to CBAVD; see above), where in particular first-degree
relatives are at risk of having the same problem and/or their disease
may have unexpected serious consequences for their offspring. These
issues are more complicated in the case of using genome-wide
diagnostic assays such as the currently used aCGH.112
For couples, the crucial question usually is the possible health-
related risk to the children to be born. Here the ‘risk tolerance’ of the
couples may be very different. For instance, in case of CBAVD, some
couples may wish to have the treatment without further investigation
of the spouse, because they do not want having their pregnancy more
‘medicalised’ despite the risk of having a child with CF. Similarly, in
cases of Y chromosome microdeletions some couples may consider
the risk of infertility for the male offspring a concerning issue,
whereas others are willing to accept this consequence in a male who
could later benefit from ICSI. In any case, an individualised approach
to counselling is of paramount importance, without disregarding the
professionals’ own responsibility to take account of the welfare of
children conceived by ART (see the section ‘Equal access, prevention
of infertility, public funding of assisted reproduction’).
A current example of one of the most complicated situations in
genetic counselling of infertile couples is related to CBAVD.113
Usually, these men have two CFTR mutations:113 one CF-causing
(hence serious) mutation, which in homozygosity or a compound
heterozygous status would lead to the classical form of CF, and one
‘mild’ mutation or variant in trans. This combination typically leads
to CBAVD with no other features of CF which determines the
phenotype. If ICSI is performed with sperm of such an individual, the
offspring will inherit either one of those mutations. If the spouse also
carries a CF-causing mutation, where the carrier frequency is of the
order of 1/25–30 in most European-derived populations, the offspring
has a 1/4 risk of inheriting CF, while male offspring will have an
additional 1/4 chance of inheriting CBAVD. If neither of these
situations is acceptable to the couple, as many as 25–50% of the
embryos may turn out to be ‘affected’.
Another problem is that genetic testing for CFTR mutations in the
spouse is complicated. Optimally, when predefined population
specific testing panels are used (eg, using commercial diagnostic
assays) she may be found to carry a mutation with defined clinical
consequence.114 However, if sequencing is carried out she may be
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found to have a mutation (eg, missense or splicing) and/or variant of
unclear clinical significance. Furthermore, even if no mutations are
found in the CFTR gene, there may be rarer CF-causing mutations,113
which are not present within used assays or the pathogenic variant
may reside in the intron. Importantly, most CFTR diagnostic assays
had been optimised for Western European populations and thus have
decreasing mutation detection rates in Southern- and Eastern Europe.
Examination of intra-CFTR rearrangements adds to the complexity of
diagnostic testing in CF. All this may be difficult for the couple to
comprehend and it markedly increases the burden of their ART
treatment and makes genetic counselling more challenging.
Some couples opt for ART treatment, because the fetus is at high risk
for a genetic condition and they wish to avoid termination of
pregnancy (TOP). These couples may have undergone genetic counsel-
ling previously, at the time of the diagnosis of the disease in their
family, and may be aware of the disease in the family and their risk of
having an affected child. If such a couple is considering PGD, genetic
specialists (medical geneticists and genetic counsellors/nurses) ideally
should meet the couple again before the possible treatment for further
counselling. PGD is only one of several options available to couples that
wish to avoid having an affected child; others include having no
children, having no genetic testing, having prenatal diagnosis (PND)
potentially associated with TOP, using donor ova or sperm, or
adoption. There is, at present, a paucity of research into the experiences
of couples who have used PGD. However, a recent Australian study
reported, in 14 women who had used PGD, that it had enabled them to
feel more empowered with regard to their reproductive lives.115
Decisions regarding the use of PGD are based on cognitive
appraisals, emotional responses and moral judgments. For instance,
when couples have the task of dealing with risk-based information,
conflicting emotions and their own moral perspectives have a major
influence on their decision about accepting or declining PGD;
therefore, quality of care for couples requires counselling that
incorporates these three aspects of their decision.116 It is important
that the option of PGD is mentioned during genetic counselling in all
relevant cases, as the couple’s attitude towards using this technique
cannot be assumed. Patient-oriented research has indicated that
couples wish to have the option presented to them by a health
professional. Couples who have experienced PND and TOP
previously may be more likely to consider PGD, as may those who
already have an affected child.115 Those who wish to avoid TOP may
also see PGD as a viable option. On the other hand, there are also
some couples who wish for a pregnancy that is ‘natural’, if possible,
and who would therefore decline the use of this technique. PGD
should be the method of choice to avoid transmission of the
condition, where couples with a genetic risk need IVF because of
infertility. Finally, costs of PGD, eventual necessity for successive
confirmatory PND (due to the possibility of misdiagnosis), together
with the necessity to undergo IVF, constitute major limiting factors
for the fertile couple.
Genetic counselling before PGD is complex.117 This may be due to
the combination of significant family and genetic history and
complicated reproductive history, often involving loss of previous
affected children or multiple TOP. Adequate information to make a
decision must be provided, and some couples who have used PGD
reported wanting more information than they were given.115 The
experience of the condition in the family needs to be explored and
acknowledged, as this may have a powerful impact on the decision. It
is also important to acknowledge that there may be no ‘right’ or
wrong’ decisions, especially in the context of decisional conflict
associated with the choice to have PGD.116
Conflict may also exist between the partners, especially if they bring
different moral perspectives. The role of the genetic counsellor is to
support the couple in coming to a decision that takes into account
their values and beliefs. Perhaps uniquely among the health profes-
sionals involved, the genetic counsellor is also required to address
wider family issues, to identify others in the family who might be at
risk, to discuss how this information may be disclosed and, if
appropriate, to arrange to offer cascade testing to other family
members (see the section ‘Ethical issues related to assisted reproduc-
tion and reproductive genetics’).
The recommendations on provision of PGD indicate that genetic
counselling should be provided by trained professionals. In some
countries (eg, in Canada), this is already being provided by genetic
counsellors,118 and it would appear that these professionals are
appropriately equipped to provide this service. In Europe, there has
been a variation in the development of the genetic counselling
profession in each country. Recently, coordinated European
initiatives110 are facilitating common standards of genetic
counselling practice and education. Moreover, establishment of the
European Board of Medical Genetics within ESHG, which aims to
ensure the highest levels of competence of physicians, scientists and
counsellors working in medical genetics across Europe and to enhance
their mobility by the development of portable EU-wide qualifications,
will ensure harmonisation of counselling related to PGD.
PGD and PGS
PGD is a diagnostic test used to select genetically or chromosomally
normal embryos for patients at high risk of transmitting a specific
abnormality to their children. Even though these patients will often be
fertile, they have to undergo IVF/ICSI to generate embryos in vitro,
which will be biopsied, and these cells will subsequently undergo
genetic testing. The disease or chromosome abnormality needs to be
previously identified, so that specific (targeted) genetic testing could
be performed. Embryos that are free from the disease tested will be
transferred into the uterus.
PGS is an adjunct to IVF and is used to aid embryo selection for
certain groups of patients, including those with advanced maternal
age, repeated IVF failure, repeated miscarriage with normal karyo-
types in the parents and severe male factor.
For both PGD and PGS, there are three stages during which cells
can be removed for genetic testing.119 Polar body (PB) biopsy involves
the removal of the first and/or second PB, either simultaneously at the
zygote stage or sequentially at the oocyte and then zygote stage. The
major limitations of PB biopsy are that only maternal chromosomes
are analysed. Some centres only examine the first PB, but this will not
give a complete picture, as errors may also occur during meiosis II. PB
biopsy is the most time consuming of all biopsy techniques, as all
mature oocytes should be biopsied, some of which will not proceed to
fertilisation or cleavage. PB biopsy renders the largest amount of
samples to be examined compared with other biopsy techniques,
especially if both PB are examined.120 This technique has mainly been
developed in some countries (eg, Germany) with legal constraints for
embryo selection.
To date, the most commonly used biopsy technique has been
cleavage-stage biopsy, which is performed on day 3 of development,
when the embryo is at the seven- to eight-cell stage.22,121 A hole is
drilled in the zona pellucida and usually only one blastomere is
aspirated. This technique allows the analysis of the embryonic
genome (specific genes or chromosomes), but is complicated by the
high levels of chromosomal mosaicism that occurs at this stage of
preimplantation development. This is especially an issue for
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aneuploidy screening, as in 50% of cases or more human
preimplantation embryos exhibit at least two different cell lines.
Therefore, the biopsied cell might not be a representative of the
remaining embryo.
Blastocyst biopsy is being increasingly used.122,123 A hole is made in
the zona pellucida, either on day 3 or day 5, and the trophectoderm is
allowed to herniate through the hole. Around five trophectoderm cells
can be removed and used for the genetic analysis. Blastocysts exhibit
less mosaicism but only around half of the embryos will reach the
blastocyst stage, whereas in some patients blastocysts do not develop.
Freezing biopsied embryos has recently become very successful with the
increasing use of vitrification.124 In some cases, all the biopsied embryos
are vitrified, leaving more time for the genetic testing to be performed
and also allowing samples to be sent to expert PGD centres for analysis.
Historically, two main techniques have been used for the genetic
analysis in PGD:125 a PCR-based test for single-gene defects126 and
FISH to examine chromosomes (for PGD of translocations and
PGS).127 More recently, arrays have replaced FISH to examine
chromosomes.128 Methods used in genetic testing in PGD/PGS have
to be both robust and sensitive in order to be able to obtain a reliable
result from a single or few cells. DNA contamination have to be taken
into careful consideration.129
PCR-based techniques have developed over the last 20 years in
order to allow a growing spectrum of diseases to be diagnosed at the
single-cell level. Sensitivity has increased by using fluorescent primers
and mini-sequencing or real-time PCR in mutation detection often
combined with the analysis of linked DNA markers. PCR protocols
have to take into account amplification failure, contamination and
allele dropout, which is an extreme form of preferential amplification
of a respective allele.126
Preimplantation genetic haplotyping is a clinical method of PGD,
which involves whole-genome amplification (WGA) of the biopsied
material and analysis of multiple microsatellite markers linked or
optimally flanking the mutation site, in order to provide a more
practical, yet accurate (due to a low risk of recombination), indirect
approach to mutation analysis.130
FISH analysis of chromosomes in PGD/PGS has limited diagnostic
accuracy and is now rarely used.127 FISH has been replaced by aCGH,
which allows all chromosomes to be examined.125 In aCGH, the
biopsied samples first undergo WGA, and the test and control
samples are fluorescently labelled. Both samples are hybridised onto
an array chip that may contain bacterial artificial chromosome,
P1-derived artificial chromosome or yeast artificial chromosome
clones, and results are simple to read, showing the copy number of
chromosomes.131–134
SNP arrays can be used for single-gene disorders by linkage
analysis, as well as for aneuploidy screening.135–137 However, the
couple, and sometimes even their parents, have to be tested to obtain
their haplotype in order to establish the linkage phase. The amount of
information obtained is immense and it can also potentially detect
predispositions to common diseases, physical characteristics and late-
onset disorders. Its current limitation has been due to the increasing
discovery of multiple CNVs of unknown clinical significance, which
complicate counselling and often leave patients with unanswered
questions. In this regard, detected CNVs should be added to
international databases, such as DECIPHER,138 to enable assessment
of their pathogenic potential through compilation of independent
data on their clinical association.
PGD has several limitations when performed in fertile couples, as it
is time consuming, stressful and, so far, rather costly if not covered by
health insurance and/or health care systems. Occasionally, patients
will only produce affected embryos; hence, there will be no available
embryos to be transferred.
The main advantage of PGD is that it provides improved
reproductive choice to the couple, thereby overcoming the possibly
difficult decisions related to selective TOP. Couples should be made
aware of the fact that embryo selection has to be performed based on
the exclusion of selected genetic traits, whereas other traits are not
accounted for. Because of the complex nature of PGD, there have been
cases of misdiagnosis, some of which are caused by technical errors,
whereas others are due to biological issues, such as mosaicism.129 It is
therefore advisable that couples should be informed about the
possibility to verify PGS/PGD results by standard PND or, more
recently, by non-invasive prenatal testing (NIPT)/non-invasive
prenatal diagnosis (NIPD) techniques within the early phase of
pregnancy.139 The advantage of the latter technique is that it
obviates the need to invasively sample fetal material by chorionic
villus sampling or amniocentesis.140
The use of oligo-/SNP arrays and WES/WGS analyses will allow a
substantial increase in the amount of genetic information that will
become available from each embryo. In this context, it also needs to
be noted that interpretation challenges will increase with high-
throughput genomic techniques, as will the chance for the detection
of incidental findings.141 These rapid technological developments will
necessitate development of novel guidelines, interpretation algorithms
and ethical frameworks (see the section ‘Ethical issues related to
assisted reproduction and reproductive genetics’). NIPT using cell-free
fetal DNA and cell-free fetal RNA will improve the possibility to verify
the PGD result in case of pregnancy and may possibly alter the
demand for PGD/PGS in the future.142
PGS has increasingly been used in the past decade. Mastenbroek
et al8 conducted a meta-analysis on the effect of PGS on the live-birth
rate per patient. RCTs comparing IVF with and without PGS were
included. FISH analysis was used in all trials and cleavage-stage biopsy
was used in all but one trial. PGS significantly lowered live-birth rate
after IVF for women of advanced maternal age (risk difference:
0.08; 95% CI: 0.13 to 0.03). For a live-birth rate of 26% after
IVF without PGS, the rate was between 13 and 23% using PGS. Trials
where PGS was offered to women with a good prognosis and to
women with repeated implantation failure suggested similar
outcomes. The possible explanations for this observation are that
the biopsied blastomere is not a true representation of the embryo at
the eight-cell stage due to mosaicism, the biopsy procedure might
cause harm and negative influences on the developmental potential of
the biopsied embryo or FISH analysis did not allow examination of all
chromosomes.143–145 To eliminate the problem of mosaicism at the
blastomere stage, two approaches are possible: PB biopsy and
trophectoderm biopsy. ESHRE conducted a proof-of-principle study
to validate the use of aCGH for aneuploidy screening146 and has
initiated a multicentre PB RCT using aCGH for advanced maternal
age (ongoing at the time of publication).
Recent studies have suggested that biopsy of several trophectoderm
cells from the blastocysts, followed by aCGH, might represent an
optimal strategy for aneuploidy screening. The main question
concerns the rate of mosaicism at the blastocyst stage and to what
extent this might cause misdiagnoses. In a recent study, 42.3% of
blastocysts were uniformly euploid, 30% were uniformly aneuploid
and 32.4% were mosaic. Of the mosaic embryos, 15.4% were found to
be composed of a mixture of different cell lines, whereas 17%
contained both normal and aneuploid cells.131 In the first
prospective RCT directly measuring the predictive value of PGS, the
clinical error rate was very low (4%), whereas implantation and
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delivery rates of euploid embryos were increased relative to the entire
cohort of transferred embryos.147 Another group of authors9
conducted a pilot RCT using blastocyst biopsy and aCGH-based
PGS in a small group of young, good prognosis, patients. The authors
demonstrated increased ongoing pregnancy and implantation rates as
compared with a control group, but the control group showed a
lower-than-expected pregnancy rate. This study included elective
single embryo transfer in both arms. At this stage, it is too early to
conclude whether a 24-chromosome screening is of value.
Furthermore, it has to be shown which biopsy stage gives a better
result: PB or trophectoderm.
The ESHRE PGD Consortium has analysed over 35 000 cycles of
PGD/PGS since 1997.22,121 The PGD Consortium has reported an
increase in the quantity of PB and blastocyst biopsy, in the list of
diseases diagnosed, and how the technology for diagnosis has evolved.
The PGD Consortium has several working groups that are looking at
follow-up of untransferred embryos, how the data is collected, how
arrays are used, implementation of accreditation, and introduction of
molecular methods and the outcomes of pregnancy.148
The Consortium has recently produced guidelines in four indivi-
dual documents that can be read and considered together. Alterna-
tively, each one of them could also be used individually. The four
topics covered include the organisation of a PGD/PGS centre,
amplification-based PGD, FISH-based PGD and embryology, as it
relates to PGD and PGS.119,126,127,149 The Consortium have also
produced a guide to PGD laboratory accreditation (Harper et al150;
see the section ‘Accreditation of laboratories in the field of
reproductive genetics’).
PGD should always be part of the information about reproductive
options (together with PND, NIPT/NIPD,151 adoption and all other
options) in preconception genetic counselling to couples and relatives
from families with hereditary diseases. This includes information
about the whole process, including the burden, invasiveness, limited
success rate, cost and unknown risks for all those involved. The pros
and cons of PGD must be properly balanced by honest information
provision. Pre- and post-test genetic counselling should be performed
in an adequate setting. Referral to a specialised psychologist should be
made whenever needed.1
Genomic variation in early human development and related
diagnostic techniques
It is by now well established that chromosomal abnormalities are
inherent to human embryos. FISH analysis on human embryos
detected a large incidence of abnormal blastomeres in normally
developing, good quality, cleavage-stage embryos from IVF
patients.152–154 A similar proportion of aneuploidy has been
detected in embryos derived from normal fertile couples.155–157
Meta-analyses reviewing 36 studies, in which all blastomeres of
cleavage-stage embryos have been analysed by at least 8 FISH
probes, show that only 22% of embryos are euploid,158 with an
increase up to 45% in blastocysts.131 Considering the mitotic error
rate during the cleavage stage, analysis of single blastomeres will not
provide insight in the genomic constitution of the other cells, nor in
the developmental potential of the embryo.159,160
Aneuploid numbers of locus-specific FISH probe signals were in
general interpreted as whole-chromosome imbalances, thereby
neglecting the possibility of structural chromosomal aberrations. It
was with the development of metaphase aCGH that the extent of
whole-chromosome imbalances could be probed genome wide. For
the first time also, segmental chromosome imbalances were reported
in B7 to 32% of embryos.161–164 aCGH has increased the resolution
for single-cell analysis, revealing an even higher incidence of
segmental rearrangements.135,159 As this high incidence was only
observed in a limited series of studies, more investigations are
warranted and technological advances are needed to (1) identify its
true incidence, (2) associate the type and incidence with the referral
reasons and (3) identify the origins of those imbalances.
Currently, two novel technologies are likely to further change our
approach and ethical view towards genetic testing of embryos. First,
the gradual introduction of WES/WGS testing into diagnostic practice
will enable selection against embryos that will be affected by
‘Mendelian’ (or rare) disorders, but will indirectly result in a
genome-wide view of the future of the developing embryo.136,165
Second, single-cell WES/WGS sequencing of individual blastomeres
(or similarly sequencing small numbers of blastocyst cells) will
provide the most in-depth view of the human genome at early
stages of human development.166,167 It is important to assess the
evolutionary, medical, ethical and legal consequences of these novel
technologies in both clinical and community genetics and assisted
human reproduction168–170 (see sections ‘Ethical issues related to
assisted reproduction and reproductive genetics’ and ‘Legal issues
related to assisted reproduction and reproductive diagnostics’).
Accreditation of laboratories in the field of reproductive genetics
The primary function of clinical genetic testing laboratories is to
produce accurate and timely test results. However, data from genetics
external quality assessment (EQA) schemes for many disorders reveal
serious errors leading to misdiagnosis, typically concerning 1–5% of
results for EQA samples. Errors of essentially all types are observed:
misidentification of samples, false-positive and false-negative geno-
typing errors, misclassified mutations and serious errors of inter-
pretation or of genetic nomenclature.171–175
The effects of an error in a genetic test can be significantly greater
than that in other fields of laboratory medicine. Specific tests of the
germline genome are typically performed once in a lifetime, and the
results concern not only the tested individual but also untested relatives
and offspring. Consequently, a genetic testing error can become fixed in
the medical record of the patient and of other family members.
Proactive quality assurance (QA) should be implemented to meet
the expectations of the consumers for reliable services. Quality
standards need to be defined at the international, European and/or
national level, both for laboratory procedures and other elements of
ART, including counselling in the area of reproductive medicine and
reproductive genetics.103
QA in genetic testing laboratories has many components, both
technical and organisational. Licensing refers to the permission or
permit from a governmental agency to operate a laboratory. Details
vary between legislations but it does not typically involve evaluation
of quality management and technical competence. Certification,
typically according to ISO 9001,176 attests compliance to a quality
management system, but is not required to address technical compe-
tence, which severely limits its value in laboratories. Accreditation is a
procedure by which an authoritative national body gives formal
recognition that a laboratory is competent to carry out specific tasks.
It involves expert audit of technical competence and quality
management. The most appropriate accreditation standard for
medical diagnostic laboratories is ISO 15189.11 Accreditation to this
(or an equivalent) is considered as the single, most effective route to
comprehensive laboratory QA as stipulated by the OECD ‘Guidelines
for Quality Assurance in Genetic testing’.10
Validation and verification are closely related concepts that
represent one of the fundamental differences between clinical and
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research laboratories. Validation and verification refer to the proce-
dures used to confirm, through the provision of objective evidence,
that a specific test performs as it should. In genetics, verification
particularly concerns Conformite´ Europe´enne (European Conformity;
CE)-marked in vitro diagnostic devices (IVDDs).33,177 In this regard,
it confirms that within a particular laboratory the specified
performance is attained. Validation is broader in scope, in that it
requires an evaluation of all aspects of testing and, most importantly,
accuracy: trueness and precision for quantitative tests, or sensitivity
and specificity for qualitative ones.178 When a new diagnostic test is
developed the laboratory must validate it, to show that it is suitable
for the intended use and that it achieves the required performance.
Another laboratory that implements the same test would verify locally
that they obtain the same performance. Validation is a formal
requirement of ISO 15189 (section 5.5.2): ‘The methods and
procedures selected for use shall be evaluated and found to give
satisfactory results before being used for medical examinations’. In
addition, many European countries have legal requirements for
accreditation and or validation,172 (eg, including Belgium, Czech
Republic, France, Germany and Switzerland), which unfortunately
tend to be mostly poorly known and loosely enforced. A survey of
usage of CE-marked IVDD assays for CFTR gene testing revealed that
only one-third to one-half of respondents performed in-house
verification of CE–IVDD before their use in routine diagnostics.172
The main role of EQA is to establish interlaboratory compar-
isons. Samples with mock clinical cases are sent to participants
who test and report according to their standard practice. The
accuracy of testing and reporting are evaluated. This permits
independent evaluation of laboratory performance, while provid-
ing continuous education. EQA and other methods of interlabora-
tory comparison are a formal requirement of ISO 15189, but are
rarely required by legislation.
Laboratory personnel need to be competent before performing
clinical testing. Competence requires a combination of training
(initial and continuous) and experience. The laboratory should
perform all testing using an authorised standard operating procedure
(SOP), which provides clear and easily understandable instructions
for the procedure. The SOP should also provide clear instructions
concerning the internal quality control requirements of the test,
covering the totality of in-house procedures performed, to eliminate
potential mistakes by verifying that the intended quality is achieved in
each test, in every run.
The survey of QA practices in 53 European PGD laboratories
revealed that only 33% of laboratories described themselves as
‘accredited, certified or preparing for accreditation’, and 66% as not
participating in EQA, a problem which was exacerbated at that time
by the absence of existing PGD-specific schemes.179 The ESHRE PGD
Consortium reacted rapidly to develop and encourage better QA, with
a network of partner organisations: (a) PGD-specific EQA schemes
are now available, (b) training workshops addressing the accreditation
of PGD laboratories are held regularly, (c) the Consortium has
formally recommended that all PGD laboratories should be accredited
or working actively towards accreditation (ISO 15189) and (d) a
guidance document has been published.150
A more recent survey by the EuroGentest2 consortium of mole-
cular genetic testing laboratories in Europe revealed that only 23% of
responding laboratories were accredited, and that 22% did not
participate in any genetics EQA schemes.180 More encouragingly,
the quantity of accredited laboratories had doubled in 5 years.174 The
OECD,10 ESHRE128 and the CF Network181 currently recommend
that all laboratories issuing genetic test results should be accredited.
DTC genetic testing at the interface of genetics and reproduction
Within the healthcare domain, genetic tests are usually performed in a
clinical (medical) genetics centre or other entities (public or private)
recognised or certified by national healthcare systems, where due
emphasis is provided on the individualised medical supervision of
patients. In addition, pretest and post-test counselling (mostly
performed by appropriately certified, clinical/medical geneticists,
genetic counsellors or nurses), psychological follow-up and QA of
genetic tests are assured.182 In contrast, within the last several years
primarily commercial entities have been increasingly advertising and
selling genetic tests either DTC or providing them to their customers
in a ‘DTC-through-physician’ (ie, via a non-specialist) manner.183,184
DTC genetic testing can be defined as the advertising and selling or
(free) provision of genetic tests DTCs. As suggested by the former
United Kingdom Human Genetics Commission, this also includes
‘tests that are commissioned by the consumer’ outside the healthcare
system, but where a medical practitioner or a health professional is
involved in the ordering of the tests or the provision of the test result.
The range of DTC genetic tests available is broad, including for
instance carrier tests for (1) rare genetic disorders, (2) ‘lifestyle’-
related genetic traits, (3) pharmacogenomics, (4) NIPT, (5) paternity,
(6) ‘romantic relationship’ testing, (7) genomic risk profiles for many
conditions, or (8) ‘recreational’ ancestry or genealogical tests.14 These
different types of tests bring different practical and ethical concerns.
At the technical level, the different companies also use different
strategies. Although various companies only look at a small number
of known SNPs, others analyse 500 000 or more SNPs. On the basis of
the knowledge of statistical associations with genetic variants, they
provide consumers with information about their susceptibility for
specific health conditions or traits.185
With the decreasing prices of WES/WGS, it is expected that DTC
companies will be offering WES/WGS in the near future to their
clients. In particular, WGS poses ethical problems, because it basically
provides complete information about an individual genome.186 This
means that, potentially, every single trait or disorder ever associated in
the past (or ever to be associated with in the future) with a SNP or
other genomic alteration could be identified.
These tests have the potential to identify every single individual,
that is, gamete donors and recipient children, that seriously challenges
anonymity and privacy.187 Genomic technologies together with
electronic media and communication are redefining the concept of
anonymity in medicine and society.188 Another concern, highlighted
by the recent case of ‘racial purity testing’ in Hungary189 emphasises
the need for regulation and ethical governance within the scientific
and/or diagnostic communities.
These developments basically compound all the ethical and social
issues raised by the genetics of common multifactorial and single-
gene defects. The sheer volume of novel information and the present
substantial deficit of expertise to interpret and communicate this
information, as well as the absence of any structured framework to
manage these data, make it imperative that the ethical and social
issues be addressed as soon as possible. Two types of information that
can be accessed through DTC genetic testing companies are particu-
larly challenging at the interface between genetics and reproduction:
(1) carrier tests and (2) identification of relatives.
First, various commercial companies presently offer DTC carrier
tests for recessive genetic disorders.190 Identifying carriers of
autosomal recessive or X-linked disorders before pregnancy has the
potential to benefit prospective parents. It offers carrier couples the
possibility to make informed reproductive decisions before pregnancy,
without the emotion and pressure associated with prenatal screening
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and offering maximum reproductive options. These include not only
PND, followed (or not) by TOP or accepting the risk, but also
deciding to refrain from having children, adoption, using donor
sperm or eggs, and PGD.191 For example, preconception carrier
screening (PCS) for CF is recommended by the American College of
Medical Genetics,192 together with the American College of
Obstetricians and Gynaecologists,193 for couples with no family
history of this condition.194 This type of screening is not currently
in practice in Europe195 within the national healthcare systems, which
might accelerate implementation of commercial offers outside of
them.
However, the commercial offer of carrier testing through the
internet creates various challenges. First, the large number of
disorders that are included in most of the panels contrasts with the
limited amount of disorders that are usually suggested to be screened.
The current offer challenges at least two important criteria196,197 that
are usually used as the basis for population screening: (1) the
condition should be an important health problem and (2) there
should be a suitable test with known predictive value. Second, an
internet offer provides challenges regarding provision of information,
in particular whether this is sufficient, balanced, reliable and
understood by the users. Third, although most companies are
focused on providing online test results, they refer customers to
their individual physicians or clinical genetics centres for further
interpretation of test results. Not only does this disconnect such
service tests from their usual embedding in a medically supervised
context, as it might create a downstream effect on the healthcare
system, with individuals procuring genetic counselling, this issue now
seriously challenges the capacity of healthcare-based genetic services
to cope with an increased influx of counselees where it is difficult to
distinguish the degree of their risk. Moreover, it is not clear whether
people who seek DTC testing are naturally concerned owing to their
family history, or are just ‘curious’. Fourth, concerns exist whether the
provision of information through a website is an appropriate
replacement for pre- and post-test counselling, in particular when
such results include information that is difficult to interpret. Fifth,
concerns revolve around the fact that DTC companies also perform
genetic testing in minors. Sixth, the majority of these companies
‘disclaim’ any responsibility for the quality of their service, test
accuracy, customer support/advice and medical implications of their
results.198–200 This is in clear opposition to the ethical
recommendations regarding testing minors, which emphasise
delaying testing in children, unless there is a clear medical benefit
for them. In the case of carrier testing, this ‘should be discouraged
until the minor has the maturity and competence to understand the
nature of the decision and its implications, and is able to consent’.201
Finally, various companies have developed tools whereby indivi-
duals can find biological relatives via social networks or share genetic
information.202 Thus, individuals can trace relatives who they might
have been looking for or even might not have known existed. Success
stories have been described, in which people have found first-
degree203 or second-degree relatives.204 The more samples and
information is stored by these commercial companies, the more
individuals will be able to link up with distant relatives or very close
relatives, such as siblings or parents. For adoptees or children
conceived through gamete donation, this offers the possibility to
trace unknown biological parents and other relatives. Although
various countries have given up anonymity of gamete donors,205
others hold on to a model based on anonymous gamete
donation.138 With increasing technical possibilities, promises with
regard to anonymity of donors become increasingly difficult to fulfil.
Further debate will be necessary to discuss the implications of these
techniques regarding provision of information on biological relatives
to children conceived via ART or in adoptees.
Epigenetic effects related to ART
One of the recurrent questions in ART is focused on the issue as to
how much this medical technology could affect the epigenome of
human embryos produced in vitro. The epigenome comprises the
complete set of non-covalent modifications onto the genetic material
of a cell or an organism.206 These epigenetic marks or modifications
correspond to molecular modifications of the DNA, such as
methylation of cytosines and modification of proteins associated
with DNA such as histone methylation, acetylation and deacetylation,
and phosphorylation, without affecting the DNA sequence per se.
Epigenetic marks often affect transcriptional activity and control
developmental plasticity of cells, including cell-type-specific gene
expression patterns.207,208 Epigenetics also studies alterations that
may be stable throughout the lifetime of an individual. Epimutations
are mitotically heritable changes not involving the DNA sequence and
associate with the abnormal increase or decrease in the methylation
status of a given gene, which may influence its qualitative and/or
quantitative expression. Restoration of the epigenome, which is
compatible with the totipotency found in the germline, requires
two waves of epigenetic reprogramming: (a) during ontogeny of
primordial germ cells; and (b) during preimplantation embryonic
development.209 Both reprogramming events are relevant for ART, as
they can interfere with the quality of gametes or be relevant to in vitro
culture of human embryos.
Studies on animal models have clearly established that environ-
mental factors, such as superovulation, culture medium composition
and/or embryo manipulation, might affect the epigenome and impact
on the conceptus, including neonatal birth weight. Animal models,
such as mouse and cow, commonly suffer from the so-called
‘large-offspring syndrome’.210–212 In humans, more studies are
needed to corroborate initial discrepant observations with regard
to low-birth-weight babies following ART.213 Observed phenotypic
effects are mainly due to aberrant methylation and/or gene expression
patterns.214 Most of the abnormally expressed genes were differentially
imprinted.210,211,215
Genomic imprinting is a process through which alleles of given
genes are expressed in a parent-of-origin-specific manner. Genes that
are subject to imprinting often have key roles in embryonic develop-
ment and behaviour. In humans, several defects in imprinted genes
are linked to syndromes such as Beckwith–Wiedemann (BWS; MIM
130650), Prader–Willi (PWS; MIM 176270), Angelman (AS; MIM
105830) and Silver–Russell syndrome (SRS; MIM 180860). Increased
prevalence of imprinting disorders related to ART has been reported
during the last decade, but most often without proper reference to the
primary cause of infertility and methods (ICSI and culture media)
used in ART. Indeed, cases of BWS, AS and PWS syndromes were
described after intrauterine insemination, IVF and ICSI, after fresh or
frozen embryos transfers at different stages of development (days 2, 3
or 5), and following different stimulation protocols.21,216–218
A Swedish study on a large cohort of children born after IVF found
seven cases of imprinting disorders (one BWS, two SRS and four
PWS) out of a total of 31 850 children. Among 6052 children studied
through the Danish National Cohort, no imprinting disorders were
reported. However, BWS and AS syndromes were not analysed in this
cohort.219 These studies need further follow-up and, most
importantly, standardised methodology.
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It is possible that ART may affect the epigenome in a more general
way, having different and longer-term consequences. Most promi-
nently, inheritance of an epimutation may result in transgenerational
effects, the results of which can be demonstrated only after multiple
generations.
A summary of the evidence on imprinting and ART shows that
absolute risks appear to be low, whereas animal studies have
established their biological plausibility (see above). The influence of
ART on the status of the epigenome is not yet completely under-
stood.220 ESHRE understands and is supporting initiatives for RCTs
of culture media and their impact on early epigenetic programming in
the embryo. This may also be relevant when evaluating imprinting
defects after ART.
Epidemiological aspects: birth defects and population genetics
Although ART helps to achieve a successful pregnancy, it is associated
with a slightly elevated risk of birth defects, multiple pregnancies
(leading to pre- and dysmaturity) and may contribute to an increase
of the genetic causes of fertility problems in the future. To evaluate the
pros and cons of ART, prospective, large cohort, lifelong, multi-
generational and multicentre follow-up studies would be extremely
important,1 and this issue needs to be addressed at the international
level.
One of the best known adverse effects of a medical treatment for
the next generation are the limb-reduction defects caused by
thalidomide, where the relative risk is 175.221 When considering the
size of studies needed to properly evaluate potential increases of birth
defects, we must realise that most monitoring programmes are
limited in their ability to detect new teratogens, that is, agents
which can disturb the development of an embryo or fetus.
A monitoring system covering 25 000 births per year could identify
a ‘new thalidomide-like agent’ in a few weeks.221 Most drugs known
to increase risks of birth defects have much lower relative risks. Thus,
for valproic acid and isotretinoin, with a relative risk ranging between
20 and 25, more than 20 years of monitoring would be needed. The
adverse effects of diethylstilbestrol became apparent only after a few
decades, as the health effects (eg, clear-cell carcinoma and uterine
anomalies) became apparent only in adulthood.222 Recent
publications have mentioned imprinting disorders as a potential
health effect of ART220 (see the section ‘Epigenetic effects related to
ART’). Here too, a long time may be needed to study the scope of
their diverse health effects.
Statistical power in epidemiological studies is optimised by
classifying birth defects into aetiologically homogeneous groups and
expanding the sample size of the monitored population.221 Many
studies evaluating the potential adverse health effects of ART present
data per country and add up all birth defects, irrespective of their
aetiology. Increased risks of imprinting defects, such as the BWS and
AS, with a prevalence around 1:15 000, will not become apparent
between the total of all birth defects monitored (2–3%).212,220 Studies
need to look into larger populations and into specific effects, and
importantly with a standardised methodology.
In a systematic review of outcomes after ICSI, eight relevant studies
were identified: two studying karyotypes and five reporting mal-
formations.220 In total, there were 55/1973 (2.8%) abnormal
karyotypes in the ICSI group with ejaculated sperm, 0/31 in the
ICSI group with epididymal sperm and 5/191 (2.6%) in the ICSI
group with testicular sperm. Major malformations were found after
ICSI in 543/12 377 (4.4%) in the ejaculated sperm group, 17/533
(3.2%) in the epididymal sperm group and 31/670 (4.6%) in the
testicular sperm group. Although these show that over 95% of infants
do not have these health problems, they have no statistical power to
exclude an increase in specific birth defects.
Recently, a large registry-based study analysing the birth defects
registry in the United States, including 1% of ART in the population
and 13 500 infants with birth defects, was carried out. Among
singleton births, ART was associated with septal heart defects
(adjusted odds ratio (aOR)¼ 2.1; 95% CI, 1.1–4.0), cleft lip with or
without cleft palate (aOR¼ 2.4; 95% CI, 1.2–5.1), oesophageal atresia
(aOR¼ 4.5; 95% CI, 1.9–10.5) and anorectal atresia (aOR¼ 3.7; 95%
CI, 1.5–9.1).223
Outcomes of pregnancies after IVF were studied in Sweden over a
period of 25 years and revealed a decrease of multiple pregnancies, a
decrease of preeclampsia and premature rupture of membranes, and
an increased risk for cerebral palsy, possibly for attention-deficit and
hyperactivity disorder, for impaired visual acuity and for childhood
cancer, although stressing that these outcomes were generally rare,
even after IVF.224
Couples using ART have, in general, a higher prevalence of aberrant
karyotypes than the general population, have more mutations of the
CFTR gene and show more Y chromosome microdeletions (see the
section ‘Genetic aspects of male fertility’). These causes of infertility
may be passed onto the successive generation if medical techniques
are used to achieve successful pregnancies. The main question is
whether it could be considered a medical/social problem if 1% of
pregnancies carry an increased risk of infertility into the next
generation. If infertility treatment will be even better than it is today,
these aberrant karyotypes, Y-chromosomal deletions and/or carrier of
CFTR gene mutations may hardly affect the overall quality of life.
Epidemiological studies225 may help to identify and address some
increased risks, such as multiple births, preterm delivery or newborn
birth weight. Nonetheless, if any other increased risks could be
avoided, this should become policy. Population genetic effects (ie,
transgenerational effects) are mostly unknown, thus far. To decide
whether or not increased risk exists, or whether or not they are
avoidable or acceptable, more interdisciplinary research is needed.
Human embryonic stem cells and induced pluripotent stem cells:
pitfalls and promises for regenerative medicine and disease
modelling
Pluripotency is usually defined as the ability of a cell to differentiate
into derivatives of the three germ layers. Human embryonic stem cells
(hESC) are the best-known example of pluripotent cell lines,226 and
are, for the largest part, derived from the inner cell mass of 5- to 6-
day-old blastocysts. These are usually originating from surplus
embryos after IVF treatment. A particular example comprises hESC
lines derived from embryos shown to be affected by a single-gene
defect after PGD. Alternative sources have been described, such as
hESC derived from a single blastomere biopsied from a cleavage-stage
embryo, or from parthenogenetically activated oocytes. A major
breakthrough in the field was the demonstration that terminally
differentiated somatic cells, such as fibroblasts, could be
reprogrammed into a pluripotent state to a great extent
indistinguishable from hESC, by the induced expression of only
four key pluripotency genes (OCT4, KLF4, SOX2 and C-MYC). Many
observers consider these induced pluripotent stem cells (iPSC) to be
the future replacement of hESC, as they do not carry the negative
connotation of embryo research and embryo destruction that burden
the utilisation of hESC.227
Of significant importance to researchers in the field of single-gene
defects are the pluripotent cells that carry a single-gene defect.228
hESC derived from affected PGD embryos are an important resource
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of these, but the major drawback here is that they are only available
from embryos in which PGD has been performed. This approach
rules out the majority of rarer single-gene defects, as well as
multifactorial diseases. In contrast to hESC, iPSC can be generated
from any individual that suffers from a disease of interest and several
iPSC lines can be obtained from different patients with different
genetic backgrounds. They can be differentiated in vitro into any
tissue, including tissues that are difficult to obtain from patients, or
are hard to culture such as brain tissue and cardiomyocytes.229 Thus,
hESC and iPSC that carry a particular disease represent promising
new disease models, especially for those single gene or multifactorial
diseases for which no good animal models exist.
In past years, an increasing body of evidence has accumulated
showing that hESC and iPSC suffer from genomic instability that is
reminiscent of cancer cells, in particular testicular germ cell tumours.
They quickly acquire trisomies, especially for chromosomes 12 and
17, small recurrent amplifications in chromosome 20 (Spits et al230)
and mitochondrial mutations,231 and their epigenome changes
haphazardly.232 These adverse effects, on the capacity of these cells
to terminally differentiate or generate possibly malignant tumours, are
poorly understood. Further work is still needed to establish optimal
culture conditions that prevent or limit this instability. This is of vital
importance if these cells are to be used in a clinical setting and to
ensure their reliability as research models.233 Concurrently, robust and
higher-throughput screening tests need to be developed in order to
assess the genomic/chromosomal stability of stem cells in vitro, for
research, diagnostic, and eventually for therapeutic purposes.
Equal access, prevention of infertility and public funding of
assisted reproduction
Although a requirement of equity, equal access to assisted reproduc-
tion for those with similar reproductive needs is still not a reality in
Europe. Restrictive national legal provisions lead to increased CBRC23
(see the section ‘Cross-border reproductive care’) and create further
barriers and social injustice. The EU and its Member State (MS)
national health authorities should enable equal access to ART and
PGD, as part of regular health care and favour education about
infertility, genetics and reproductive options.25,35,233
Reproductive health is a great value to the community.234 Infertility
and increased genetic risk for disease are serious health threats, which
deserve appropriate attention and action. The primary goal of ARTs
and genetics is to restore reproductive confidence for couples
facing these difficulties.1 Reproductive confidence can only be
communicated to the public, provided that: (1) evidence on
potential risks is acquired; (2) truthful and accurate information is
provided to the couples through reproductive or genetic counselling
(as appropriate); and (3) quality of laboratorial and clinical services is
closely monitored by accreditation and use of standard success-rate
endpoints.
Prevention of infertility should become a priority goal of EU
healthcare systems, in addition to social measures to counter, for
example, increasing parental age, drug abuse (including tobacco and
alcohol), sexually transmitted diseases, obesity, environmental factors,
etc, as reviewed elsewhere for males and females.235–237 Earlier
parenthood should be made easier by societal changes to facilitate
the possibility of combining earlier childbearing with a successful
professional career, including broad-scale education of young adults
of the negative impact of ageing on reproductive performance237 and
on increasing respective risks/burden.238 Economic hardship and
insufficient social support for young couples have been increasing
during the last decade and contribute to the tendency to postpone
procreation to a later age. In general, these negative developments
increase risks for pregnancy, decrease fertility (thereby increasing the
need for ART) and augment the risk of transmission of chromosomal
and hereditary diseases related to higher maternal and paternal age to
the offspring.
Barriers to adoption as a possible alternative to assisted reproduc-
tion are still tangible and there is a lack of incentives to change this.239
A better and more widespread education about genetics (at all school
levels and in society at large, educating about the role of genes,
environment and other factors) should help in decreasing the
concepts of genetic determinism/exceptionalism in medicine240 and
of general medicalisation of life, thereby increasing the individual and
social acceptance of adoption. The adequate role of genetics in
healthcare systems, including promotion of public awareness on
recent advances in genetics and of their impact on the general
population, were comprehensively outlined in the Council of Europe
(CoE) ‘Recommendation CM/Rec (2010)11 of the Committee of
Ministers’ to MS on the impact of genetics on the organisation of
healthcare services and training of health professionals,182 in the
drafting of which several members of ESHG and ESHRE were
involved.
On the other hand, decreased costs and (at least partial) reimburse-
ment of hormonal stimulation and infertility treatment (if sustained
under current economic pressures) may increase the uptake of ART
and PGD.24,241 Access to appropriate fertility treatment should
become a part of basic human rights242 for the benefit of current
and future generations.243
The need for public funding of assisted reproduction can be argued
in various ways. For instance, Israel’s pronatalist policy of offering
nearly full funding for IVF to any Israeli woman until she has two
children with her current partner, is based on cultural, religious and
demographic considerations.244 Recently, population policy
arguments for funding IVF have also surfaced in the European
debate. Following the recommendations of the 2006 RAND study,
increasing the use of ART would be a means to increase fertility and
thus reduce the economic costs of population aging.245 However,
most accounts of whether and why society should pay for assisted
reproduction refer to views about how the need for such treatment
relates to notions of a fair distribution of scarce healthcare
resources.246 Much of the debate has turned on how this ‘need’ is
to be understood. Following the influential views elaborated by
Daniels,247 a case for funding-assisted reproduction may be based
on the notion of ‘restoring equality of opportunity’ by eliminating the
arbitrary and undeserved effects of ill health on ‘normal species
functioning’. On a strict reading, this line of reasoning will limit
reimbursement to cases of infertility caused by a disease or a
biological dysfunction. The view adopted by ESHRE’s Task Force
on Ethics and Law is that procreation is an important goal in life and
that medical assistance to help people achieve this goal responds to a
fundamental human need.25 On wider accounts of ‘health’,
reimbursement of those dependent on such help can be justified
even if their childlessness may not be caused by a disease or
dysfunction. This should also include reimbursement of IVF/PGD
when there is a high risk of a serious handicap or disability. On the
basis of this reasoning, affluent societies can be expected to include
assisted reproduction in their public funding schemes.170
Nevertheless, taking account of restricted budgets and valid claims
to inclusion of other kinds of health care or other fundamental needs,
rationing is inevitable, also from a justice perspective.25 Criteria for
rationing may include minimal effectiveness, amount of treatments/
cycles to be reimbursed and secondary infertility/number of children.
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The application of those criteria raises difficult issues both of
fairness (eg, greatest efficiency versus highest need) and of equity
(eg, minimal-effectiveness threshold ideally based on all relevant
factors).
The field has a responsibility to contribute to enlarging access to
assisted reproduction by efforts to increase effectiveness and reduce
costs, especially when services are publicly funded. Patients also have a
responsibility to avoid unnecessary consumption of publicly funded
health care as a result of lifestyle-related factors that are known to
affect fertility and successful treatment. It is not unfair to insist that a
serious effort at achieving lifestyle modification must be made before
treatment can be considered. However, limiting access to publicly
funded treatment because of lifestyle factors should be based on
evidence rather than prejudice.248
Ethical issues related to assisted reproduction and reproductive
genetics
Professionals providing reproductive treatments are not merely
concerned with solving or managing a medical problem, they also
causally and intentionally contribute to the birth of a child. It is
generally accepted that this has implications for professional respon-
sibilities, as, for example, reflected in the amended British Human
Fertility and Embryology Act,249 where it is stated that ‘treatment
services shall not be provided unless account has been taken of the
welfare of any child who may be born as a result’. There has been
some debate about what precise standards should be used in this
connection.250 ESHRE’s Task Force Ethics and Law has defended a
‘reasonable welfare standard’, according to which fertility professionals
should refrain from participating in reproduction only in cases where
there would be a high risk that the future child would have a seriously
diminished quality of life.105 This not only applies to situations where
there are serious doubts about the psychosocial parenting capacities of
those requesting help, but also to cases in which medical, including
genetic, conditions would entail ‘a high risk of serious harm’. For
instance, how to think about cases where couples of which one of the
partners is a carrier of the fully penetrant allele causing Huntington’s
disease (HD), ask for IVF/PGD in order to select a mutation-free
child? Is providing this treatment acceptable in the light of the
implications for the child of the fact that the carrier parent will
inevitably develop HD? The authors of a recent review recommend to
consider this on the basis of the specifics of individual cases, taking
account of factors including the actual condition of the carrier
(symptomatic or not yet) and the coping skills of the other partner.251
Professional co-responsibility for the welfare of the child marks an
important difference between the normative framework of medically
assisted reproduction and that of traditional genetic counselling, with
its emphasis on professional non-directiveness.252 Whereas in PND it
is generally accepted that professionals should not put any pressure on
prospective parents to have PND, offering IVF on the condition of
also doing PGD may be acceptable in cases where professionals would
otherwise feel obliged to refrain from providing assisted
reproduction.253 Possible examples are cases where the male partner
carries a balanced chromosome translocation involving a high risk for
the future child, or where both partners are carriers of CF or some
other serious recessive disorder. Transfer decisions are a further area
where different views may lead to conflicts between fertility
professionals and intended parents. Most PGD centres adhere to
the rule that no transfer will be done if no non-affected embryos are
available. The recently updated ESHRE PGD Consortium Guidelines
indicate that further specifications, for example, with regard to
dynamic mutations where mutation size may have a phenotype/
genotype correlation, or with regard to embryos found to be carriers
of recessive disorders, need to be explained as part of pretreatment
counselling. This would ensure that couples are fully informed about
how transfer decisions will be made, so that conflicts about this can
be avoided.149
Since the previous joint ESHG–ESHRE position statement,1 the
same ethical issues have continued to be discussed. Fundamental
criticism of IVF and PGD is still raised by those who regard human
embryos as having the full moral status of persons, and/or object to
what they see as a philosophy of non-acceptance of the equal worth
of those living with genetic disorders and handicaps. However, the
tendency is one of increasing acceptance that these arguments are
not convincing and that technologies allowing people with fertility
problems to have their genetically own children, or allowing those
at genetic risk to reproduce with confidence, should be regarded as
morally valuable. That still leaves room for continuous debate
about the scope of acceptable applications. Whereas in Germany
legal rulings and political debate have now made PGD possible
(with the first child being born in January 2012), but only for
hereditary conditions that lead to miscarriage or stillbirth,254 in
many other countries the range of accepted conditions has been
expanded to include common disorders with a genetic
predisposition that accounts for a less than complete but still
high penetrance, such as hereditary cancer syndromes.
Considerations behind the reasoning that conditions must be
serious enough to qualify for PGD are the fact that embryo
testing and selection requires burdensome and costly IVF
treatment (often, in part, subsidised from public or collective
funds), the moral sensitivity of embryo selection, concerns that the
procedure (including embryo biopsy) may have subtle adverse
long-term health effects and the fear that allowing PGD for less
serious conditions would be a step on a slippery slope towards the
dreaded ‘designer child’.255,256
This last argument is also behind the view that PGD should be
bound to a strict ‘medical model’, allowing only applications aimed at
avoiding a (serious) health problem in the child to be. However, as
the distinction between medical and non-medical allows for ‘inter-
mediate cases’, a strict interpretation of this model may rule out too
much.257 For instance, PGD for human leukocyte antigen typing in
order to conceive a ‘saviour sibling’ for a child with a life-threatening
disorder258 may well be morally acceptable even if PGD is not done to
(also) avoid this disorder in the child to be.259 Moreover, attempts at
more precisely delineating the medical model in terms of ‘seriousness’
should take account of the fact that this is not an entirely
objective criterium, given the extent to which the seriousness of
a condition depends on individual circumstances and subjective
understandings.260
Ethical questions of a different kind are raised by the possible
application of PGD for disorders caused by a mitochondrial DNA
defect.261 Although PGD for such disorders greatly improves the
probability of an unaffected pregnancy, it cannot guarantee that the
child will not be affected by the very conditions that were tested
for.262 This not only implies a rethinking of the traditional aim of
PGD but entails difficult weighing of pros and cons in concrete cases,
also in the light of a professional responsibility for the welfare of the
child.263 The alternative route of maternal spindle transfer (MST) or
pronuclear transfer (PNT; forms of gene-replacement therapy aimed
at reconstructing eggs or one-cell embryos with healthy
mitochondria) that are currently under investigation may provide a
way to avoid these problems, but not without putting new ethical
debates on the agenda.264
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There is a growing awareness in the field that the introduction of
new reproductive technologies requires more evidence about their
efficacy, safety and cost-effectiveness than has been collected in the
past, as well as long-term follow-up of clinical data.125 As stressed by
ESHRE’s Task Force Ethics and Law, this directly connects to the
moral duty of fertility specialists to take into account the welfare of
the children they help to conceive.105 A continuous and explicit
commitment from the field to the ideal of responsible innovation is
also a matter of societal accountability and a prerequisite for
maintaining the trust of the public.169 Innovations should first be
tested in preclinical animal and embryo studies for efficacy and safety,
including other forms of ART.28,169,265,266 As this may also require
research involving the creation of human embryos, the fact that this
type of embryo research is forbidden in many countries (as well as by
the European Convention on Human Rights and Biomedicine267)
poses a hurdle for the responsible introduction of new technologies
that are now on the horizon, such as MST/PNT for mitochondrial
disorders and the possible reproductive use of gametes derived from
pluripotent stem cells in the future.268 The reasoning behind this
prohibition is difficult to sustain given the broad consensus about the
relatively low moral status of the preimplantation embryo as
presupposed in the justification of IVF itself.169 When, after
sufficiently reassuring preclinical studies, new technologies or
treatments are introduced into clinical practice, this should ideally
take the form of clinical studies aimed at prospectively collecting
uniform data. Large, prospective, collaborative multicentric
efforts, as well as cohort studies, are strongly recommended to
assess effectiveness and long-term safety, including possible
transgenerational health effects (see the section ‘Epigenetic effects
related to ART’). Ethical, legal, social and psychological research in
the field is also needed in order to reflect changes in practice and the
influence of social media (web2) communication channels.269 Further
research of these aspects is necessary, in particular given the rapid
spread of such information/communication technologies, together
with the paucity of evidence-based information websites.270
The European Commission (EC) and MS national health autho-
rities and funding agencies should encourage research aimed at
gaining evidence on the benefits and potential risks of ART
techniques, both for the future child (eg, imprinting-related dis-
orders) and to future generations (transgenerational effects and
dysgenesis due to transmission of male infertility and disease-
associated mutations) as discussed above.
As remarked above, cascade screening is an effective strategy for
identifying persons at risk of developing and transmitting genetic
disorders that are highly frequent in affected families.271 This
includes diseases such as hypercholesterolaemia272 and hereditary
cardiac arrhythmias.273 Cascade screening has also been considered
for FXS (see the section ‘Genetic aspects of female infertility’).
There has been some debate about the ethics of offering cascade
screening in families affected by such genetic disorders. A specific
concern was that the uninvited nature of the screening offer might
entail an invasion of the ‘right not to know’ of individual family
members. However, depending on the disease in question and the
amount of harm that a timely warning could help avert, the ‘right
to know’ of family members at risk may well be the morally
weightier consideration.259
PCS can be a useful tool for informing couples that they may be at
a high risk of having a child with an autosomal recessive disorder (eg,
CF and haemoglobinopathy). As indicated above, European health
systems seem hesitant to develop this option, leaving the field to
commercial initiative. It can be asked whether this is wise. Given that
children with these disorders are often born to non-suspecting
parents, providing the option of preconception testing for carrier
status of selected recessive disorders (those with a higher frequency in
the specific population) could have important benefits, both in terms
of providing options for reproductive choice and preventing avoidable
suffering. Integrating this in a wider reproductive health policy will
allow setting conditions for a qualitatively sound and ethically
responsible screening offer.274 As already pointed out, technological
developments will allow carrier status to be simultaneously
determined for a large spectrum of recessive conditions, without
significantly increasing the costs of testing275 (see the section ‘DTC
genetic testing at the interface of genetics and reproduction’). The
question is indeed whether or to what extent such ‘comprehensive’
PCS will fulfill the criteria for responsible screening (see the section
‘Equal access, prevention of infertility and public funding of assisted
reproduction’). Clearly, broad-scope PCS leading to couples making
far-reaching reproductive decisions on the basis of test results of
which the clinical implications are not yet fully understood, is morally
unacceptable.276
Another area at the interface of assisted reproduction and genetics
is the selection of gamete donors, as recently reviewed, for example,
by The Practice Committee of the American Society for Reproductive
Medicine.277 As more diseases with a strong genetic component are
now being identified, and as there are increasing technical capacities
to detect them, the question arises whether the present guidelines for
genetic donor screening need revision.278 Case reports of serious
genetic disorders occasionally being found in donor offspring or
(past) donors also lead to calls for expanded screening.279
Nevertheless, it is still uncertain how far should we could go in
genetic screening of potential donors. Clearly, a ‘zero-risk’ approach is
unrealistic and is bound to lead to false reassurance in recipients.
Moreover, as this would lead to excluding most if not all donors, such
an approach would be counterproductive and disproportional.
Relevant ethical issues not only relate to the interests of the
prospective parents and the child to be, but also to those of the
donor. For instance, with the prospect of broad screening based on
genome-sequencing techniques, there is a risk of findings predictive of
disorders that the donor (and his close relatives) may experience as a
threat without meaningful options.280 Respect for autonomy would
require donors to be informed about the possible implications of
testing, both for themselves and for their close relatives. A specific
question concerns the scope for allowing a meaningful ‘right not to
know’. Counterselected donors need to be offered genetic- and
reproductive counselling. Donors need not be excluded because of
heterozygosity for rare (‘Mendelian’) autosomal recessive diseases,
because they can be matched with suitable recipients. However, in this
instance the cost of additional genetic testing may have an impeding
role.
New ethical issues can be expected to arise as a result of the
introduction of arrays and WES/WGS in the context of PGD and PGS
(see the section ‘PGD and PGS’).125,128,281 A possible future scenario
is that the distinction between PGD for single-gene defects and PGS
will disappear and that one ‘universal’ genome analysis will routinely
be offered to all those seeking assisted reproduction, possibly in
combination with preconception testing.282 From an ethical point of
view, this scenario not only raises concerns about the feasibility of
adequate pretest counselling and informed consent (a challenge also
in other clinical contexts where new comprehensive genomic testing
technologies are currently being introduced), but also requires a
further rethinking of the aims of PGD/PGS.17,252 Which
abnormalities, beyond those for which the couple may be at a high
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risk and/or those directly affecting treatment success, should IVF
embryos be routinely tested for and why? Obviously, the fact that per
cycle only a limited number of embryos will be available for selection
entails that with wider testing, all embryos will in some way be
‘affected’. But that does not rule out the possibility of selecting the
best available embryo based on comparative genomic health profiles.
Whereas some will be concerned that this brings us further on a
slippery slope towards an unhealthy perfectionism,283 others have
argued that prospective parents have a prima facie duty to use medical
technology in order to select, from the possible children they could
have, those whose lives can be expected to go best.284 How to think of
the role of the fertility professional in a possible scenario of
comprehensive embryo testing? Should doctors insist on using these
technologies in order to ensure that after IVF, only the embryos with
the best genetic make-up are allowed to grow into a child? Clearly,
there is scope here for difficult conflicts between professionals and
prospective parents about what tests to perform and which embryos
to select.
A specific issue in this connection is that comprehensive testing of
embryos may lead to finding predispositions for late-onset disorders
for which no adequate options for treatment or prevention exist.
Apart from the probability that one of the intended parents will have
the mutation as well, a difficult problem would arise if an embryo
with such a finding were to be selected for transfer.257 Arguably, the
quality of life of the resulting child would be seriously affected by this
knowledge. Moreover, it would be denied the right to decide for him
or herself, once mature enough to do so, about what to be tested for.
For both these reasons, current ESHG guidelines stipulate that
predictive testing for such disorders should not be done in
minors.198,201 If that is the case, would it be acceptable to bring
children into the world with a positive outcome of the same kind of
testing? This need not mean that embryos may not be tested for the
relevant predispositions. But it would seem that such testing would
only be acceptable with the aim of non-selection of carriers. Some of
the moral problems of WES/WGS testing-based PGS may be avoided
with the alternative strategy of offering preconception screening to
prospective parents followed by targeted PGD in case of high risk.
Obviously, the ethics of this approach needs further scrutiny.274
Legal issues related to assisted reproduction and reproductive
genetics
Since 2006, many countries in Europe have enacted or modified laws
on assisted reproduction and/or genetic testing, many of these
containing provisions on PGD, taking into account the accumulating
scientific knowledge and rapid development of ART techniques.
Despite the general shift to more permissive regimes, major differ-
ences still exist in Europe.234 Currently PGD is banned in Austria and
Switzerland, whereas jurisprudence and interpretation of laws is
affecting practice in Germany,285 Ireland and Italy (see legal Acts
below). Allowed indications for PGD also vary in other countries to a
great extent. The diversity of regulation maintains the need for
CBRC23 and is also pertinent with regards to the application of
patient rights in cross-border healthcare.286
The following laws have been adopted or modified since 2006 in
Europe – Belgium: Act 6/7/07; Czech Republic: Acts 227/2006Sb, 372/
2011Sb (‘Za´kon o zdravotnı´ch sluzˇba´ch’) and 373/2011Sb (‘Za´kon o
specificky´ch zdravotnı´ch sluzˇba´ch’); Finland: Act on Assisted repro-
duction 1237/2006; France: LOI no 2011-814 du 7 juillet 2011 relative
a` la bioe´thique; Germany: Gen DG 2009 and Embryo Protection Act
(1990) amendment 2011 (see above); Italy: Supreme Court Decision
of 2009 modified reading of Act 2004 (Corte Constituzioale 2009,
Sentenza N. 151);287 Portugal: Act 32/2006 (Procriac¸a˜o medicamente
assistida); Spain: Ley 14/2006 (Sobre te´cnicas de reproduccio´n
humana asistida); and Sweden: Lag om genetisk integritet (2006:251).
Special attention should be paid to the quality of culture media for
human embryos. Safe handling is specifically dealt with by the
EUTCD and the supplementing technical directives 2006/17/EC30
and 2006/86/EC31 that set standards on quality and safety of
handling with reproductive cells, fetal tissues and cells, and adult
and embryonic stem cells.
EC Directive 98/79/EC33 on IVDD is also applicable to genetic tests
but not to in-house assays developed and used in the same facility.
The manufacturer of an IVDD device must comply with the essential
requirements and follow a conformity-assessment procedure of the
appropriate risk category as set forth in the directive. The directive
requires that manufacturers notify the competent authorities of the
placing on the market of ‘new products’ with regard both to the
technology used and the substances to be analysed or other
parameters; high-density DNA probe devices (known as microchips
or arrays) used in genetic screening are mentioned as particularly
essential in this regard. The directive is currently under revision and it
is anticipated that DTC genetic tests (see the section ‘DTC genetic
testing at the interface of genetics and reproduction’) will be raised to
a higher-risk category, meaning that they have to meet more stringent
criteria in the future.
Recently, attention has been drawn to the ethical aspects of
preconceptional and prenatal genomic testing in many countries,
such as by the Health Council of the Netherlands168 and the Nordic
Committee on Bioethics.288 The main worries relate to the lack of
clinical application (within the ACCE framework (Analytic validity,
Clinical validity, Clinical utility and associated Ethical, legal and social
implications framework for evaluation of genetic tests))289,290 for the
majority of tests and the fact that patients/consumers may not receive
balanced pretest information. Given the size of the potential market,
commercial offers may downplay the risks and exaggerate potential
benefits. Moreover, genetic and reproductive health services are
not ready to cope with the increasing workload, or ‘flood’ of
preconceptional and fetal gene screening tests.291
There is accumulating case law from the European Court of Human
Rights (ECHR) in the field of ART providing interesting argumentation
about rights and European consensus.292 The common argument in the
applications to the Court is the violation of Article 8 of the European
Convention of Human Rights,293 when a procedure or reproductive
treatment is refused by a national entity. This article states the
following: ‘8.1 Everyone has the right to respect for his or her
private and family life’; ‘8.2 There shall be no interference by a
public authority with the exercise of this right except such as is in
accordance with the law and is necessary in a democratic society in the
interests of -for the protection of health and morals,...’.
Rulings of ECHR have constantly declared that the contracting
states have a broad margin of appreciation in moral issues when
European consensus does not exist, but they have to justify their
approaches and strike a fair balance between competing private and
public interests. One of the latest cases, SH and others v. Austria
(ECHR 57813/00, judgement 3 November 2011),294 regarding the use
of heterologous gametes for IVF, is particularly interesting in its
argumentation.295 ECHR stressed the current need for a wide margin
of appreciation due to sensitive moral and ethical issues against a
background of fast-moving medical and scientific developments
(point 97). But in point 118, ECHR stated ‘- this area, in which the
law appears to be continuously evolving and which is subject to a
particularly dynamic development in science and law, needs to be kept
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under review by the Contracting States’. This seems to be a clear
message that countries cannot eternally adopt legislation against the
mainstream once principles in the field of ART would become ‘settled
and longstanding’ at a certain stage (point 96), although the
mainstream is far from obvious and differences persist between
European countries.
Professional societies, such as ESHG and ESHRE, have developed
good practice guidance/guidelines to reflect a common understanding
of the scientific, ethical, legal and social issues that are important to
be acknowledged as due diligence in their field (see their websites for
continuous updates). Even though such guidance has not been
developed in a regular normative process by a sovereign legislator,
they may gain normative legal relevance. The CoE ‘Oviedo Conven-
tion’267 (see the section ‘Ethical issues related to assisted reproduction
and reproductive genetics’) provides a clear mechanism for making
such guidelines legally relevant for the contracting states, as Article 4
requires, that ‘Any intervention in the health field, including research,
must be carried out in accordance with relevant professional
obligations and standards’. Moreover, guidelines and guidance may
become used as benchmarks for the standard of care in medical
negligence actions if shown to be ‘a usual and normal practice’.296
Europe is still fragmented with regards to regulation on ART. The
rulings of ECHR may, in time, affect somewhat the states’ margin of
appreciation. Until people can access services in their own countries,
CBRC offers a choice, at least for motivated well-informed patients
with the stamina and the necessary means.
CONCLUSIONS
The interface between ARTs and genetics has become more
entwined as we increase our understanding about the genetics of
infertility, and we are able to perform more comprehensive genetic
testing. This continually evolving field requires communication
between the clinical genetics, IVF teams and patients to ensure that
they are fully informed and can make well-considered choices. The
genetic basis of male and female infertility will help diagnose the
cause of infertility. Moreover, against the background of reports
about possible subtle health effects that may be related to
epigenetic modifications, there is a growing awareness that the
introduction of new reproductive technologies and treatments
needs to be based on sound preclinical and clinical research aimed
at collecting evidence about their efficacy and (long-term) safety, as
well as their cost-effectiveness. Comprehensive genetic testing of
the embryo before implantation raises complex clinical and ethical
issues. Couples may increasingly undergo a whole-genome scan
before an IVF (or natural) cycle, and if any serious risk is detected
they can decide which reproductive option would suit them best.
The possibility of performing a whole-genome scan for PGD may
be around the corner and would also allow for the detection of de
novo mutations. As IVF clinics gain higher success rates and genetic
diagnosis helps the treatment of infertile couples, there will be need
of much discussion regarding which procedures are clinically and
ethically acceptable, and how these are regulated. Through these
discussions, we must develop sound international policies, facil-
itate harmonisation of legislation and regulatory practices, includ-
ing equal access to medically assisted reproduction in Europe, and
beyond.
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